Emily’s Entourage Announces Chandrabali Ghose, PhD, as First-Ever Chief Scientific Officer
Dr. Chandra Ghose will lead the organization’s research and development activities to speed therapeutic developments for individuals with rare forms of cystic fibrosis (CF)
Lower Merion, PA – Emily’s Entourage (EE), an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of cystic fibrosis (CF), announces the appointment of Dr. Chandra Ghose as the organization’s first-ever Chief Scientific Officer. In this new role, Dr. Ghose will define the organization’s research priorities, build and cultivate alliances with stakeholders including academic, industry, nonprofit and government entities, and manage the growing grant and investment portfolio.
“Despite the development of groundbreaking treatments for many people with CF, 10% of people with CF are left with no treatments. Emily and her Entourage’s vision and relentless pursuit for finding fast breakthroughs and a cure for every single person living with CF is inspirational,” Dr. Ghose said. “I am looking forward to leveraging my experience as a scientist-turned-entrepreneur in my new role.”
Before joining Emily’s Entourage, Dr. Ghose was the founder and CEO of Bioharmony Therapeutics, an early-stage biotech startup specializing in the development of novel antimicrobials to combat drug-resistant bacterial infections. She spent eight years at the Aaron Diamond AIDS Research Center, an affiliate of Rockefeller University, where she focused her research on developing life-saving vaccines in the laboratory of Dr. David Ho. Prior to that, Dr. Ghose was a postdoctoral fellow at Harvard Medical School in the Division of Infectious Diseases, Massachusetts General Hospital. Dr. Ghose earned her Ph.D. from New York University School of Medicine in microbiology and her bachelor’s degree from Saint Louis University in biology and theology.
“Welcoming Dr. Ghose to our team as our first-ever Chief Scientific Officer marks a historic moment for Emily’s Entourage and the CF community. It reflects our unwavering and deepening commitment to accelerating lifesaving research and therapeutic development for those in the final 10% of the CF community, with a focus on those with CF nonsense mutations,” said EE Co-Founder, Emily Kramer-Golinkoff. “With Dr. Ghose’s unique combination of deep scientific expertise, entrepreneurial background, and passionate leadership, we feel more hopeful than ever about the future of the CF therapeutic landscape for the final 10%.”
In addition to her diverse range of biomedical research, Dr. Ghose has published high-impact articles and book chapters in the field of infectious diseases, and has received many awards for her scientific and entrepreneurial contributions. She has volunteered her time at the C. Diff Foundation and at the Pew Charitable Trust’s program of “Supermoms against Superbugs” to raise awareness about antibiotic resistance, a cause close to her heart. She is also a Fellow of the fourth class of the Health Innovators Fellowship at the Aspen Institute and a member of the Aspen Global Leadership Network.
###
About Emily’s Entourage
Emily’s Entourage (EE) is an innovative 501(c)3 foundation that accelerates research for new treatments and a cure for nonsense mutations of Cystic Fibrosis (CF), a fatal genetic disease primarily affecting the lungs and digestive system. Since 2011, EE has awarded millions of dollars in research grants, launched a CF gene therapy company that was acquired by a pharmaceutical company, developed a CF nonsense mutation patient registry and clinical trial matchmaking program to speed clinical trial recruitment, and led worldwide efforts to drive high-impact research and drug development. The organization has been featured in national media, including The New York Times, STAT, CNN, People and more.
Learn more about Emily’s Entourage at emilysentourage.org.
